---
title: "Predicting acetaminophen hepatotoxicity in NAC-treated patients using routine admission biomarkers"
id: "medrxiv-6-prediction-of-acetaminophen-induced-hepatotoxicity-in-acetylcysteine-treated"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-prediction-of-acetaminophen-induced-hepatotoxicity-in-acetylcysteine-treated"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.16.26358122v1?rss=1"
published_at: "2026-07-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Predicting acetaminophen hepatotoxicity in NAC-treated patients using routine admission biomarkers
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-prediction-of-acetaminophen-induced-hepatotoxicity-in-acetylcysteine-treated
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.16.26358122v1?rss=1)
- **Published At:** 2026-07-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study developed a prognostic model to identify acetaminophen-overdose patients at high risk of developing **hepatotoxicity** despite treatment with **acetylcysteine** (NAC) using only routine admission blood tests. - Retrospective cohort included all acetaminophen overdose admissions (ICD-10 T39.1) to three UK hospitals from 2008–2024 with admission alanine aminotransferase (ALT) >1000 U/L reported as an inclusion parameter for data extraction; overall cohort comprised 4,705 admissions. - Outcome defined as peak ALT >1,000 U/L. The dataset was split with 25% held out as a test set (n=1,175) to evaluate model performance. - Elastic-net logistic regression models were fitted and stratified by presentation ALT. The final model used seven routine biomarkers across strata: for presentation ALT 1,500, sensitivity 89.7%), the stratified model had higher specificity (82.5% versus 62.6%) and a greater positive likelihood ratio (5.1 versus 2.4), reducing false-positive escalations from 365 to 171 per 1,000 patients. - Authors conclude the stratified routine-biomarker model outperformed ALTxAPAP across decision thresholds and could support selection of patients for intensified therapy; competing interests and ethics approvals were reported in the source. - The article is a preprint and not peer-reviewed; data and code availability were not detailed in the abstract and full text beyond statements of approvals and funding.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Prediction of acetaminophen-induced hepatotoxicity in acetylcysteine-treated patients using routine admission biomarkers View ORCID Profile Christopher Humphries, Alastair M Kilpatrick, Melisande L Addison, Jennifer A Cartwright, Marcus J Lyall, Linus J Schumacher, Stuart J Forbes, View ORCID Profile James W Dear doi: https://doi.org/10.64898/2026.07.16.26358122 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Study objective. Some acetaminophen-overdose patients develop hepatotoxicity despite acetylcysteine treatment. Established tools struggle to prospectively identify this cohort. We developed a model using only routine admission biomarkers to identify acetylcysteine-treated patients at highest risk, and compared it with the current benchmark, the alanine aminotransferase x acetaminophen product (ALTxAPAP). Methods. Retrospective cohort of all acetaminophen overdose admissions (ICD-10 T39.1) to three UK hospitals (2008-2024) with alanine aminotransferase (ALT) >1000U/L at admission. We fitted elastic-net logistic models stratified by presentation ALT. The outcome was peak ALT >1,000U/L. Performance was assessed on a 25% held-out test set and benchmarked against ALTxAPAP. Results. Of 4,705 admissions, 119 (2.5%) developed hepatotoxicity. The model used seven routine blood tests, four per stratum: acetaminophen, sodium, potassium and lymphocyte count where presentation ALT was 1,500 practice (sensitivity 89.7%), specificity was 82.5% versus 62.6% and the positive likelihood ratio 5.1 versus 2.4, more than halving false-positive escalations (171 versus 365 per 1,000 patients). Conclusion. A stratified model using only routine admission biomarkers identifies acetylcysteine-treated patients at highest residual hepatotoxicity risk, outperforming the ALTxAPAP rule across decision thresholds, supporting selection for intensified therapy. Competing Interest Statement J.W.D. holds a patent on a new single-biomarker liver toxicity point-of-care test. S.J.F. is co-founder of Resolution Therapeutics, which is developing a macrophage cell therapy product to treat patients at risk of liver decompensation. A.M.K. is a consultant to Resolution Therapeutics. C.H. previously received an Elsevier honorarium for toxicology educational article authorship and serves as advisor to the Royal College of Emergency Medicine and the Joint Royal Colleges Ambulance Liaison Committee on Toxicology. The remaining authors declare no competing interests. No commercial party had any role in study design, data access, data analysis, interpretation, or the decision to publish. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was reviewed and approved by the Edinburgh Medical School Research Ethics Committee (25-EMREC-070), with data extraction and transfer approved by the NHS Lothian Caldicott Guardian (ref. 24167). Patient and public involvement was not sought for this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes FUNDER INFORMATION DECLARED Medical Research Council, https://ror.org/03x94j517, MR/T044802/1 Chief Scientist Office, https://ror.org/01613vh25, PMAS/21/07 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Posted July 19, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Latigo’s LTG-001 Shows Phase 2 Pain Relief in Tummy Tuck Trial, Positions as Rival to Vertex’s Jou](https://medichelpline.com/clinical-feed/stat-news-1-stat-latigo-reports-mid-stage-success-for-would-be-rival-to-vertex-s-pain-drug.md)
- [Reanalysis of Prenatal Acetaminophen and Neurodevelopmental Disorders Using Bias-Correction Methods](https://medichelpline.com/clinical-feed/medrxiv-0-testing-claimed-associations-of-prenatal-acetaminophen-with-neurodevelopmental.md)
- [Predictive compaction modelling for ternary direct-compression formulations](https://medichelpline.com/clinical-feed/pubmed-42546992.md) (DOI: 10.1016/j.ijpharm.2026.127253)
- [Adverse Pregnancy Outcomes as Predictors of Long-Term Cardiovascular Disease Risk](https://medichelpline.com/clinical-feed/pubmed-42669304.md) (DOI: 10.1016/S0140-6736(26)01235-3)
- [CHILDRENS ACETAMINOPHEN (acetaminophen) suspension [Grocery Outlet, Inc.]](https://medichelpline.com/clinical-feed/dailymed-updates-35-childrens-acetaminophen-acetaminophen-suspension-grocery-outlet-inc-.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.